Nabi Biopharmaceuticals (Nasdaq:NABI) announced that its Board of Directors adopted a stockholder Rights Agreement designed to preserve its substantial net operating loss (NOL) tax assets.

Nabi Biopharmaceuticals, a biopharmaceutical company, develops vaccines for nicotine addiction in the United States. It is developing NicVAX, a proprietary investigational vaccine under Phase III clinical trials for the treatment of nicotine addiction and prevention of smoking relapse.

To read more: http://drstockpick.com/?p=21874